New drug combo tested for Tough-to-Treat prostate cancer
NCT ID NCT07389187
Summary
This early study is testing the safety and initial effectiveness of a new oral drug called LC-K76 when given alongside an immunotherapy drug (Tislelizumab) in men with advanced prostate cancer that has spread to the bones and is no longer responding to standard hormone therapies or chemotherapy. The study will enroll 10 participants who will receive the combination treatment for 24 weeks. Researchers will monitor side effects and see if the treatment can help control the cancer's growth and delay complications from bone metastases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzheng hospital
Shanghai, Shanghai Municipality, 201109, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.